A fatty molecule in breast milk might reduce cerebral palsy in premature infants, according to a study with neonatal mice.
About 60,000 babies are born before 32 weeks gestation in the United States every year, and 10% of them will develop cerebral palsy resulting from infections that damage nerve fibers deep in the brain called white matter.
While it’s known that the white matter loss will lead to neurological deficits, there is currently no treatment to help these infants avoid the outcome.
In experiments, researchers have identified a fatty molecule in breast milk that triggers a process in which stem cells in the brain produce cells that create new white matter, reversing the injury.
The study appears in the journal Cell Stem Cell. Eric Benner is the study’s corresponding author and is an assistant professor in the pediatrics department at Duke University School of Medicine. Benner says further study in a clinical trial is needed, but the finding is promising.
“Developing therapies for children—especially such medically fragile children—is very difficult to do because there are justifiably strict safety concerns,” Benner says. “The fact that this molecule is already found in something that is safe for premature babies—breast milk—is extremely encouraging.
“It’s been known that fats in breast milk benefit a child’s brain development, but there are many types of fats in breast milk,” Benner says. “This work has identified a lipid molecule in breast milk that promotes white matter development. Now, we can begin to develop a therapy that isolates and delivers this lipid in a way that is safe for the unique challenges of these infants.”
Benner is a neonatologist at Duke University and one of the co-founders of Tellus Therapeutics, a Duke spinout company developed with the help of the Duke University Office for Translation & Commercialization to bring this therapy from the bench into the neonatal intensive care unit.
The fatty molecule identified in the study will be administered intravenously to patients in an upcoming clinical trial. This is significant because many of the infants who are part of this vulnerable population also have gastrointestinal issues and cannot safely be given milk or medication by mouth.
The lipid molecule enters the brain and binds with stem cells there, encouraging the stem cells to become or produce a type of cell called oligodendrocytes.
The oligodendrocytes are like a hub that allow for the production of white matter in the central nervous system. This newly produced white matter in pre-term infants prevents the neurological damage that would otherwise impact the child’s ability to move—the hallmarks of cerebral palsy.
“The timing of brain injury is extremely difficult to predict, thus a treatment that could be safely given to all preterm babies at risk would be revolutionary,” says Agnes Chao, a former fellow in the neonatology division and first author of the paper.
“As a neonatologist, I’m so excited that I may be able to offer a treatment to families with babies that are affected by preterm brain injury who would otherwise have no other options,” Chao says.
The study had funding from the National Institutes of Health; the Jean and George Brumley Jr. Neonatal Perinatal Research Institute; the Duke Scholars Award from the School of Medicine; Duke University Center for In Vivo Microscopy; and the National Center for Advancing Translational Sciences.
Source: Duke University
